Leadership Appointment: AIxCrypto has appointed Andrew Grossman as Head of Legal, tasked with overseeing the company's legal, compliance, and governance functions, ensuring adherence to regulations in digital assets and Web3 protocols, thereby enhancing market competitiveness.
Compliance Framework Enhancement: Grossman will leverage his extensive experience in securities regulation and digital asset ecosystem architecture to help AIxCrypto protect and unlock long-term commercial value within a complex compliance environment, ensuring sustainable business operations.
Strategic Rebranding: The company recently rebranded from Qualigen Therapeutics to AIxCrypto Holdings, marking a strategic shift at the intersection of Web2 and Web3, as well as artificial intelligence and cryptocurrency, aiming to build a globally leading ecosystem.
Continued Partnership: Grossman's appointment will further strengthen AIxCrypto's collaboration with Faraday Future, supporting comprehensive regulatory alignment and ensuring the company's compliance and governance capabilities in the rapidly evolving digital asset space.
AIXC
$2.67+Infinity%1D
Analyst Views on AIXC
About AIXC
AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
